Key result
Paclitaxel DCBs cut target lesion failure ~37% versus uncoated balloons in coronary in-stent restenosis.
Why the study?
Although drug-eluting stents remain the standard in PCI, drug-coated balloons are emerging as a stent-free alternative beyond in-stent restenosis.
Do drug-coated balloons provide a safe and effective alternative to conventional strategies in coronary lesions beyond in-stent restenosis?
Do drug-coated balloons provide a safe and effective alternative to conventional strategies in coronary lesions beyond in-stent restenosis?
Effect estimate: p=0.003
Absolute Event Rate: 17.9% vs 28.6%
p-value: p=0.003
Drug-coated balloons offer a promising stent-free alternative to drug-eluting stents across a broad spectrum of coronary lesions beyond in-stent restenosis, potentially reducing stent-related complications and allowing for shorter dual antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Supports DCB as effective therapy for ISR; extends evidence for stent-free alternatives beyond ISR with shorter DAPT.
Gupta et al. (2026) conducted a review in Patients with coronary in-stent restenosis treated with drug-coated balloon versus uncoated balloon (n=600). Paclitaxel-coated drug-coated balloon (DCB) vs. Uncoated balloon angioplasty was evaluated on Target lesion failure (TLF) at 12 months (p=0.003, p=0.003). Paclitaxel-coated drug-coated balloon reduced target lesion failure to 17.9% compared to 28.6% with uncoated balloon at 12 months in patients with coronary in-stent restenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: